NASDAQ : MDCX
Medicus Pharma Ltd. — Financial statements
Healthcare · Drug Manufacturers - General · United States
Last price 2.15 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.72M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 22.69M | 17.92M | 7.65M | 4.27M | 332.03K | 258.01K |
| Research & Development | 11.89M | 7.72M | 3.53M | 193.58K | 646.38K | 1.18M |
| Operating Expenses | 34.58M | 25.64M | 11.18M | 4.46M | 978.42K | 1.44M |
| Operating Income | -34.58M | -25.64M | -11.18M | -4.46M | -978.42K | -1.44M |
| Interest Expense | -785.04K | -197.38K | -79.03K | -1.25M | -1.10M | -690.85K |
| Interest & Investment Income | 104.41K | |||||
| Other Non Operating Income (Expenses) | -11.84M | -11.84M | 670.10K | 388.31K | 76.98K | |
| EBT Excluding Unusual Items | -47.20M | -37.68M | -11.16M | -5.04M | -1.69M | -2.06M |
| Other Unusual Items | -814.76K | -887.68K | -270.42K | |||
| Pretax Income | -56.73M | -47.28M | -11.16M | -5.31M | -1.69M | -2.06M |
| Earnings From Continuing Operations | -56.73M | -47.28M | -11.16M | -5.31M | -1.69M | -2.06M |
| Minority Interest in Earnings | 67.04K | 146.00 | ||||
| Net Income | -56.66M | -47.28M | -11.16M | -5.31M | -1.69M | -2.06M |
| Net Income to Common | -56.66M | -47.28M | -11.16M | -5.31M | -1.69M | -2.06M |
| Shares Outstanding (Basic) | 682.81K | 345.68K | 192.38K | 69.59K | 37.70K | 64.34K |
| Shares Outstanding (Diluted) | 682.81K | 345.68K | 192.38K | 69.59K | 37.70K | 64.34K |
| EPS (Basic) | -82.98 | -136.78 | -57.99 | -76.37 | -44.89 | -31.94 |
| EPS (Diluted) | -82.98 | -136.78 | -57.99 | -76.37 | -44.89 | -31.94 |
| EBITDA | -11.08M | |||||
| D&A For EBITDA | 104.53K | |||||
| EBIT | -34.58M | -25.64M | -11.18M | -4.46M | -978.42K | -1.44M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 15.17M | 8.71M | 4.16M | 1.72M | 267.65K | 78.51K |
| Cash & Short-Term Investments | 15.17M | 8.71M | 4.16M | 1.72M | 267.65K | 78.51K |
| Prepaid Expenses | 1.42M | 676.12K | 758.17K | 173.72K | 15.00K | |
| Other Current Assets | 390.00K | 509.31K | 455.81K | |||
| Total Current Assets | 16.98M | 9.89M | 5.38M | 1.89M | 282.65K | 78.51K |
| Property, Plant & Equipment | 117.18K | 170.73K | 268.57K | |||
| Total Assets | 27.12M | 10.06M | 5.65M | 1.89M | 282.65K | 78.51K |
| Accounts Payable | 6.73M | 3.44M | 1.28M | 210.84K | 99.79K | 163.48K |
| Accrued Expenses | 469.85K | 1.11M | 905.29K | 404.82K | ||
| Short-Term Debt | 3.50M | 5.25M | 165.95K | 1.53M | 667.93K | |
| Current Portion of Leases | 137.33K | 145.46K | 116.32K | |||
| Other Current Liabilities | 10.85M | 9.75M | ||||
| Total Current Liabilities | 10.84M | 9.94M | 2.31M | 781.61K | 12.48M | 10.58M |
| Long-Term Debt | 18.00M | 25.86K | ||||
| Long-Term Leases | 60.14K | 205.94K | ||||
| Total Liabilities | 28.84M | 10.02M | 2.51M | 781.61K | 12.48M | 10.58M |
| Common Stock | 74.30M | 57.08M | 30.52M | 18.76M | 194.54K | 194.54K |
| Additional Paid-In Capital | 8.88M | 6.88M | 1.52M | 98.58K | ||
| Retained Earnings | -85.01M | -64.35M | -28.90M | -17.75M | -12.39M | -10.70M |
| Comprehensive Income & Other | 61.09K | 324.81K | ||||
| Total Common Equity | -1.76M | -67.55K | 3.13M | 1.11M | -12.20M | -10.51M |
| Minority Interest | 38.69K | 104.86K | ||||
| Shareholders' Equity | -1.72M | 37.31K | 3.13M | 1.11M | -12.20M | -10.51M |
| Total Liabilities & Equity | 27.12M | 10.06M | 5.65M | 1.89M | 282.65K | 78.51K |
| Total Debt | 21.64M | 5.48M | 322.27K | 165.95K | 1.53M | 667.93K |
| Net Cash (Debt) | -6.46M | 3.23M | 3.84M | 1.55M | -1.26M | -589.42K |
| Net Cash Per Share | -9.47 | 9.34 | 19.97 | 22.32 | -33.53 | -9.16 |
| Filing Date Shares Outstanding | 1.26M | 787.24K | 236.33K | 161.53K | 6.43M | 64.34K |
| Total Common Shares Outstanding | 1.20M | 503.53K | 236.33K | 161.53K | 6.43M | 64.34K |
| Working Capital | 6.14M | -47.42K | 3.07M | 1.11M | -12.20M | -10.51M |
| Book Value Per Share | -1.47 | -0.13 | 13.26 | 6.88 | -1.90 | -163.28 |
| Tangible Book Value | -1.76M | -67.55K | 3.13M | 1.11M | -12.20M | -10.51M |
| Tangible Book Value Per Share | -1.47 | -0.13 | 13.26 | 6.88 | -1.90 | -163.28 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -56.66M | -47.28M | -11.16M | -5.31M | -1.69M | -2.06M |
| Other Amortization | 111.72K | |||||
| Stock-Based Compensation | 3.29M | 1.51M | 713.12K | 98.58K | ||
| Other Operating Activities | 23.04M | 22.31M | 162.24K | 584.82K | 713.97K | 613.88K |
| Change in Accounts Payable | 3.67M | 923.55K | 808.75K | 79.09K | -63.69K | -6.66K |
| Change in Other Net Operating Assets | -2.65M | -353.88K | -775.82K | 394.01K | -15.00K | |
| Operating Cash Flow | -29.32M | -22.78M | -10.25M | -4.16M | -1.06M | -1.45M |
| Other Investing Activities | -4.62M | -4.62M | ||||
| Investing Cash Flow | -4.62M | -4.62M | ||||
| Short-Term Debt Issued | 11.87M | 5.17M | 500.00K | 1.25M | 882.38K | |
| Total Debt Issued | 29.37M | 11.87M | 5.17M | 500.00K | 1.25M | 882.38K |
| Short-Term Debt Repaid | -7.39M | |||||
| Total Debt Repaid | -12.92M | -7.39M | ||||
| Net Debt Issued (Repaid) | 16.44M | 4.48M | 5.17M | 500.00K | 1.25M | 882.38K |
| Issuance of Common Stock | 33.99M | 28.25M | 7.52M | 5.11M | ||
| Other Financing Activities | -1.05M | -790.23K | ||||
| Financing Cash Flow | 49.38M | 31.94M | 12.69M | 5.61M | 1.25M | 882.38K |
| Foreign Exchange Rate Adjustments | 81.54K | -2.97K | ||||
| Net Cash Flow | 15.52M | 4.54M | 2.44M | 1.45M | 189.14K | -565.66K |
| Levered Free Cash Flow | -16.16M | -12.14M | -5.79M | -13.97M | -282.48K | |
| Unlevered Free Cash Flow | -15.67M | -12.13M | -5.74M | -13.18M | 406.44K | |
| Change in Working Capital | 1.02M | 569.67K | 32.93K | 473.10K | -78.69K | -6.66K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 2.44M | 34.21M | 28.71M | |||
| Enterprise Value | 8.90M | 32.71M | 23.76M | |||
| Last Close Price | 1.93 | 76.50 | 121.50 | |||
| PB Ratio | 916.99 | 9.16 | ||||
| P/TBV Ratio | 9.16 | |||||
| Debt / Equity Ratio | -12.54 | 146.79 | 0.10 | 0.15 | -0.13 | -0.06 |
| Net Debt / Equity Ratio | -3.75 | -86.52 | -1.23 | -1.40 | -0.10 | -0.06 |
| Net Debt / EBITDA Ratio | 0.35 | |||||
| Quick Ratio | 1.40 | 0.88 | 1.81 | 2.20 | 0.02 | 0.01 |
| Current Ratio | 1.57 | 0.99 | 2.33 | 2.42 | 0.02 | 0.01 |
| Return on Equity (ROE) | -7,446.11% | -2,981.18% | -525.44% | |||
| Return on Assets (ROA) | -110.67% | -204.05% | -185.36% | -256.21% | -338.63% | |
| Return on Capital Employed (ROCE) | -212.40% | -20,793.80% | -334.70% | -401.20% | 8.00% | 13.70% |
| Earnings Yield | -4,299.71% | -138.19% | -38.85% | |||
| Buyback Yield / Dilution | -173.46% | -79.68% | -176.45% | -84.60% | 41.41% |